{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:02:25Z","timestamp":1793412145798,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12648-5","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:35:20Z","timestamp":1770014120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Direct-acting antiviral therapy in HCV patients: a retrospective study of the pre- and post-treatment impact in Saudi Arabia"],"prefix":"10.1186","volume":"26","author":[{"given":"Fatimah Salem","family":"Alayidh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaf Yahya","family":"Zakary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab Yusuf","family":"Al-Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharjeel","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Omar","family":"Alsaadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijah Ahmad","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batool Abdullah","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad Mousa","family":"Alhomud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad Hassan","family":"Albather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Abdullah","family":"Bataweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouf Ahmed","family":"Madkhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira Jamaan","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarmina","family":"Ehtesham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"12648_CR1","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3389\/fmicb.2017.02413","volume":"8","author":"MG Masavuli","year":"2017","unstructured":"Masavuli MG, Wijesundara DK, Torresi J, Gowans EJ, Grubor-Bauk B. Preclinical development and production of virus-like particles as vaccine candidates for hepatitis C. Front Microbiol. 2017;8:2413. https:\/\/doi.org\/10.3389\/fmicb.2017.02413.","journal-title":"Front Microbiol"},{"issue":"8","key":"12648_CR2","doi-asserted-by":"publisher","first-page":"e43924","DOI":"10.7759\/cureus.43924","volume":"15","author":"LA Bernal","year":"2023","unstructured":"Bernal LA, Soti V. Hepatitis C virus: insights into its history, treatment, challenges, and future directions. Cureus. 2023;15(8):e43924. https:\/\/doi.org\/10.7759\/cureus.43924.","journal-title":"Cureus"},{"key":"12648_CR3","doi-asserted-by":"publisher","first-page":"102255","DOI":"10.1016\/j.tmaid.2022.102255","volume":"46","author":"N Salari","year":"2022","unstructured":"Salari N, Kazeminia M, Hemati N, Ammari-Allahyari M, Mohammadi M, Shohaimi S. Global prevalence of hepatitis C in general population: a systematic review and meta-analysis. Travel Med Infect Dis. 2022;46:102255. https:\/\/doi.org\/10.1016\/j.tmaid.2022.102255.","journal-title":"Travel Med Infect Dis"},{"key":"12648_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.17265\/1548-6648\/2019.03.005","volume":"16","author":"A Hazazi","year":"2019","unstructured":"Hazazi A, Almubarak M, Albloui F, Alsaweed O, Hawsawi Y, Alseraye F. Hepatitis C virus genotyping in Saudi population. J US-China Med Sci. 2019;16:144\u201348. https:\/\/doi.org\/10.17265\/1548-6648\/2019.03.005.","journal-title":"J US-China Med Sci"},{"issue":"9055","key":"12648_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/s0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P, The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349(9055):825\u201332. https:\/\/doi.org\/10.1016\/s0140-6736(96)07642-8.","journal-title":"Lancet"},{"issue":"2","key":"12648_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/tropicalmed8020092","volume":"8","author":"NM Hawsawi","year":"2023","unstructured":"Hawsawi NM, Saber T, Salama HM, Fouad WS, Hagag HM, Alhuthali HM, et al. Genotypes of hepatitis C virus and efficacy of direct-acting antiviral drugs among chronic hepatitis C patients in a tertiary care hospital. Trop Med Infect Dis. 2023;8(2):92. https:\/\/doi.org\/10.3390\/tropicalmed8020092.","journal-title":"Trop Med Infect Dis"},{"issue":"1","key":"12648_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/13814788.2022.2056161","volume":"28","author":"N Abu-Freha","year":"2022","unstructured":"Abu-Freha N, Mathew Jacob B, Elhoashla A, Afawi Z, Abu-Hammad T, Elsana F, et al. Chronic hepatitis C: diagnosis and treatment made easy. Eur J Gener Pract. 2022;28(1):102\u201308. https:\/\/doi.org\/10.1080\/13814788.2022.2056161.","journal-title":"Eur J Gener Pract"},{"issue":"10","key":"12648_CR8","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.4254\/wjh.v7.i10.1377","volume":"7","author":"HC Li","year":"2015","unstructured":"Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol. 2015;7(10):1377\u201389. https:\/\/doi.org\/10.4254\/wjh.v7.i10.1377.","journal-title":"World J Hepatol"},{"issue":"5","key":"12648_CR9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730\u201340. https:\/\/doi.org\/10.1093\/cid\/civ396.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"12648_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.22694","volume":"49","author":"SL George","year":"2009","unstructured":"George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatol. 2009;49(3):729\u201338. https:\/\/doi.org\/10.1002\/hep.22694.","journal-title":"Hepatol"},{"issue":"3","key":"12648_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.23744","volume":"52","author":"TR Morgan","year":"2010","unstructured":"Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatol. 2010;52(3):833\u201344. https:\/\/doi.org\/10.1002\/hep.23744.","journal-title":"Hepatol"},{"issue":"9","key":"12648_CR12","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/gut.2006.094292","volume":"55","author":"T Dudley","year":"2006","unstructured":"Dudley T, O\u2019Donnell K, Haydon G, Mutimer D. Disappointing results of combination therapy for HCV? Gut. 2006;55(9):1362\u201363. https:\/\/doi.org\/10.1136\/gut.2006.094292.","journal-title":"Gut"},{"issue":"5","key":"12648_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346\u201355. https:\/\/doi.org\/10.7326\/0003-4819-140-5-200403020-00010.","journal-title":"Ann Intern Med"},{"issue":"9286","key":"12648_CR14","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/s0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958\u201365. https:\/\/doi.org\/10.1016\/s0140-6736(01)06102-5.","journal-title":"Lancet"},{"key":"12648_CR15","doi-asserted-by":"publisher","unstructured":"Selvapatt N, Brown A. A real-world intention-to-treat analysis of a decade\u2019s experience of treatment of hepatitis C with interferon-based therapies. F1000Research. 2016;5:2061. https:\/\/doi.org\/10.12688\/f1000research.9114.1.","DOI":"10.12688\/f1000research.9114.1"},{"issue":"10","key":"12648_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1089\/jir.2019.0013","volume":"39","author":"V Pedergnana","year":"2019","unstructured":"Pedergnana V, Irving WL, Barnes E, McLauchlan J, Spencer CCA. Impact of IFNL4 genetic variants on sustained virologic response and viremia in hepatitis C virus genotype 3 patients. J Interferon Cytokine Res. 2019;39(10):642\u201349. https:\/\/doi.org\/10.1089\/jir.2019.0013.","journal-title":"J Interferon Cytokine Res"},{"issue":"4","key":"12648_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4103\/1319-3767.187609","volume":"22","author":"AA Aljumah","year":"2016","unstructured":"Aljumah AA, Abaalkhail F, Al-Ashgar H, Assiri A, Babatin M, Al Faleh F, et al. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift. Saudi J Gastroenterol. 2016;22(4):269\u201381. https:\/\/doi.org\/10.4103\/1319-3767.187609.","journal-title":"Saudi J Gastroenterol"},{"issue":"Suppl 1","key":"12648_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.4103\/sjg.SJG_477_20","volume":"26","author":"SA Alqahtani","year":"2020","unstructured":"Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, et al. Saudi association for the study of liver diseases and transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol. 2020;26(Suppl 1):S1\u201340. https:\/\/doi.org\/10.4103\/sjg.SJG_477_20.","journal-title":"Saudi J Gastroenterol"},{"issue":"8","key":"12648_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.15537\/smj.2018.8.22467","volume":"39","author":"I Altraif","year":"2018","unstructured":"Altraif I. Can hepatitis C virus be eliminated by 2030? Saudi Arabia as an example. Saudi Med J. 2018;39(8):842\u201345. https:\/\/doi.org\/10.15537\/smj.2018.8.22467.","journal-title":"Saudi Med J"},{"key":"12648_CR20","doi-asserted-by":"crossref","unstructured":"Thorlund K, Druyts E, Mills E. SVR12 is higher than SVR24 in treatment-na\u00efve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. Clin Epidemiol [Internet]. 2014;49. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3897323\/.","DOI":"10.2147\/CLEP.S53302"},{"issue":"3","key":"12648_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/gastroent12030031","volume":"12","author":"S Kamel","year":"2021","unstructured":"Kamel S, Elessawy H, Ashraf O, Elbaz A, Dabbous H, El-Sayed M, et al. Effectiveness of direct-acting antivirals in treatment of elderly Egyptian chronic hepatitis C patients. Gastroenterol Insights. 2021;12(3):336\u201346. https:\/\/doi.org\/10.3390\/gastroent12030031.","journal-title":"Gastroenterol Insights"},{"issue":"7","key":"12648_CR22","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1056\/NEJMp2002126","volume":"383","author":"GJ Dore","year":"2020","unstructured":"Dore GJ, Trooskin S. People with hepatitis C who inject drugs - underserved, not undeserving. N Engl J Med. 2020;383(7):608\u201311. https:\/\/doi.org\/10.1056\/NEJMp2002126.","journal-title":"N Engl J Med"},{"key":"12648_CR23","doi-asserted-by":"publisher","unstructured":"Abo-Amer YE, Badawi R, El-Abgeegy M, Elsergany HF, Mohamed AA, Mostafa SM, Alegaily HS, Soliman S, Elnawasany S, Abd-Elsalam S. Quadruple therapy offers high SVR rates in patients with HCV genotype 4 with previous treatment failure. Adv Virol. 2020, 2020;9075905. https:\/\/doi.org\/10.1155\/2020\/9075905.","DOI":"10.1155\/2020\/9075905"},{"issue":"2","key":"12648_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"J-M Pawlotsky","year":"2018","unstructured":"Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):153\u201394. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026.","journal-title":"J Hepatol"},{"issue":"5","key":"12648_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.5144\/0256-4947.2023.308","volume":"43","author":"A Sahin","year":"2023","unstructured":"Sahin A, Akay O. Experience with direct-acting antivirals in genotype 1\u20135 infected chronic hepatitis C patients in Turkey. Ann Saudi Med. 2023;43(5):308\u201314. https:\/\/doi.org\/10.5144\/0256-4947.2023.308.","journal-title":"Ann Saudi Med"},{"issue":"5","key":"12648_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/00365521.2017.1283439","volume":"52","author":"M Castedal","year":"2017","unstructured":"Castedal M, Segenmark M, Cederberg S, Skoglund C, Weiland O. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience. Scand J Gastroenterol. 2017;52(5):585\u201388. https:\/\/doi.org\/10.1080\/00365521.2017.1283439.","journal-title":"Scand J Gastroenterol"},{"key":"12648_CR27","doi-asserted-by":"publisher","unstructured":"Bawazir A, AlGusheri F, Jradi H, AlBalwi M, Abdel-Gader A-G. Hepatitis C virus genotypes in Saudi Arabia: a future prediction and laboratory profile. Virol J. 2017;14(1). https:\/\/doi.org\/10.1186\/s12985-017-0873-7.","DOI":"10.1186\/s12985-017-0873-7"},{"issue":"3","key":"12648_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.53854\/liim-2903-16","volume":"29","author":"FAM Almosa","year":"2021","unstructured":"Almosa FAM, Alnasser AHA, Al-Tawfiq JA. Distribution of hepatitis C virus (HCV) genotypes in a Saudi Arabian hospital during the 2015\u20132020 period. Infez Med. 2021;29(3):450\u201355. https:\/\/doi.org\/10.53854\/liim-2903-16.","journal-title":"Infez Med"},{"key":"12648_CR29","doi-asserted-by":"publisher","first-page":"1285367","DOI":"10.3389\/fmicb.2023.1285367","volume":"14","author":"M Di Stefano","year":"2023","unstructured":"Di Stefano M, Ismail MH, Leitner T, Faleo G, Alwazzeh MJ, Mbisa JL, et al. A novel candidate hepatitis C virus genotype 4 subtype identified by next generation sequencing full-genome characterization in a patient from Saudi Arabia. Front Microbiol. 2023;14:1285367. https:\/\/doi.org\/10.3389\/fmicb.2023.1285367.","journal-title":"Front Microbiol"},{"issue":"42","key":"12648_CR30","doi-asserted-by":"publisher","first-page":"e01030","DOI":"10.1128\/MRA.01030-19","volume":"8","author":"MS Pedersen","year":"2019","unstructured":"Pedersen MS, Mollerup S, Nielsen LG, Jenssen H, Bukh J, Sch\u00f8nning K. Genome sequence of an unknown subtype of hepatitis C virus genotype, 6: another piece for the taxonomic puzzle. Microbiol Resour Announc. 2019;8(42):e01030\u201319. https:\/\/doi.org\/10.1128\/MRA.01030-19.","journal-title":"Microbiol Resour Announc"},{"issue":"1","key":"12648_CR31","doi-asserted-by":"publisher","first-page":"14506","DOI":"10.1038\/s41598-021-93881-7","volume":"11","author":"OA Saldarriaga","year":"2021","unstructured":"Saldarriaga OA, Dye B, Pham J, Wanninger TG, Millian D, Kueht M, et al. Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome. Sci Rep. 2021;11(1):14506. https:\/\/doi.org\/10.1038\/s41598-021-93881-7.","journal-title":"Sci Rep"},{"key":"12648_CR32","doi-asserted-by":"crossref","unstructured":"Ryani MA. Hepatitis management in Saudi Arabia: trends, prevention, and key interventions (2016-2025). Medicina [Internet]. 2025;61(9):1509. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12471344\/.","DOI":"10.3390\/medicina61091509"},{"issue":"10","key":"12648_CR33","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.jsps.2022.07.005","volume":"30","author":"SJ Alarfaj","year":"2022","unstructured":"Alarfaj SJ, Alzahrani A, Alotaibi A, Almutairi M, Hakami M, Alhomaid N, et al. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: a single-center experience in Saudi Arabia. Saudi Pharm J. 2022;30(10):1448\u201353. https:\/\/doi.org\/10.1016\/j.jsps.2022.07.005.","journal-title":"Saudi Pharm J"},{"issue":"16","key":"12648_CR34","first-page":"2388","volume":"5","author":"MAM Marie","year":"2011","unstructured":"Marie MAM. Genotyping of hepatitis C virus (HCV) in infected patients from Saudi Arabia. Afr J Microbiol Res. 2011;5(16):2388\u201390.","journal-title":"Afr J Microbiol Res"},{"issue":"1","key":"12648_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/MCG.0000000000000872","volume":"53","author":"SC Gordon","year":"2019","unstructured":"Gordon SC, Trudeau S, Li J, Zhou Y, Rupp LB, Holmberg SD, et al. Race, age, and geography impact hepatitis C genotype distribution in the United States. J Clin Gastroenterol. 2019;53(1):40\u201350. https:\/\/doi.org\/10.1097\/MCG.0000000000000872.","journal-title":"J Clin Gastroenterol"},{"issue":"1\u20132","key":"12648_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s1386-6532(00)00154-2","volume":"20","author":"AC Haushofer","year":"2001","unstructured":"Haushofer AC, Kopty C, Hauer R, Brunner H, Halbmayer WM. HCV genotypes and age distribution in patients of Vienna and surrounding areas. J Clin Virol. 2001;20(1\u20132):41\u201347. https:\/\/doi.org\/10.1016\/s1386-6532(00)00154-2.","journal-title":"J Clin Virol"},{"issue":"2","key":"12648_CR37","first-page":"26","volume":"4","author":"RMA Zayed","year":"2015","unstructured":"Zayed RMA, Hamdy NM, Al-Ajlan HH, Aref NM. Prevalence of HCV genotypes and viral load in Saudi Arabia. Int J Intern Med [online]. 2015;4(2):26\u201341. http:\/\/article.sapub.org\/10.5923.j.ijim.20150402.02.html.","journal-title":"Int J Intern Med"},{"key":"12648_CR38","unstructured":"Muallem Y. Epidemiology of HCV in Saudi Arabia and its burden on the health care system. Scribd. 2022. https:\/\/www.scribd.com\/document\/619956422\/epidemiology-of-hcv-in-saudi-arabia-and-its-burden-on-the-health-care-system."},{"issue":"1","key":"12648_CR39","doi-asserted-by":"publisher","first-page":"e52646","DOI":"10.7759\/cureus.52646","volume":"16","author":"A Almajid","year":"2024","unstructured":"Almajid A, Albarbari H, Bazroon A, Al-Awami H, Aljurayyad R, Albadran R, et al. Epidemiological perspectives: a four-year insight into hepatitis C surveillance in the Kingdom of Saudi Arabia. Cureus. 2024;16(1):e52646. https:\/\/doi.org\/10.7759\/cureus.52646.","journal-title":"Cureus"},{"key":"12648_CR40","unstructured":"World Health Organization. Hepatitis. 2024. Retrieved from: https:\/\/www.who.int\/health-topics\/hepatitis\/elimination-of-hepatitis-by-2030#tab=tab_1."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12648-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12648-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12648-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:41:19Z","timestamp":1772448079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12648-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12648"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12648-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7285246\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institutional Review Board (IRB) of King Fahad Military Medical Complex, Dhahran, Saudi Arabia. AFHER-IRB-2024-009 on April 2024. The study was conducted under the Declaration of Helsinki. As the study involved anonymized secondary data analysis of previously collected clinical records, the requirement for individual patient consent was waived by the IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including individual details, images, or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"471"}}